Diverse Clinical and Molecular Characteristics of Advanced POLE-Mutated Endometrial Carcinoma: Emphasis on Aggressive Variants and Co-Occurring Mutations - Takeaways - MDSpire

Diverse Clinical and Molecular Characteristics of Advanced POLE-Mutated Endometrial Carcinoma: Emphasis on Aggressive Variants and Co-Occurring Mutations

  • By

  • Nicolo Cavasin

  • Sami Kilzie

  • Mattia Vinci

  • Rita Trozzi

  • Camilla Nero

  • Stefano Restaino

  • Chiara Cassani

  • Sandro Pignata

  • Carmela Pisano

  • Giuseppe Scibilia

  • Robert Fruscio

  • Rosanna Mancari

  • Adolfo Favaretto

  • Matteo Fassan

  • Luisa Toffolatti

  • Giovanna Gallina

  • Francesco Fanfani

  • Vanda Salutari

  • Grazia Artioli

  • April 29, 2026

  • 0 min

Share

  • 1

    Advanced POLE-mutated endometrial carcinoma is characterized by high tumor mutational burden and typically favorable prognosis.

  • 2

    The study analyzed 14 patients with advanced-stage POLE-mutated endometrial carcinoma, all of whom had high-grade tumors.

  • 3

    Lymphovascular space invasion was present in all cases, and 64% of tumors were mismatch repair-proficient.

  • 4

    Co-mutations in the PI3K/AKT pathway were found in 29% of cases, indicating potential for aggressive disease.

  • 5

    The study highlights atypical metastatic patterns, including brain metastases, challenging the assumption of indolent behavior.

Original Source(s)

Diverse Clinical and Molecular Characteristics of Advanced POLE-Mutated Endometrial Carcinoma: Emphasis on Aggressive Variants and Co-Occurring Mutations

  • by Nicolo Cavasin, Sami Kilzie, Mattia Vinci, Rita Trozzi, Camilla Nero, Stefano Restaino, Chiara Cassani, Sandro Pignata, Carmela Pisano, Giuseppe Scibilia, Robert Fruscio, Rosanna Mancari, Adolfo Favaretto, Matteo Fassan, Luisa Toffolatti, Giovanna Gallina, Francesco Fanfani, Vanda Salutari, Grazia Artioli

  • April 29, 2026

Related Content

Immune biomarker landscape and fusion partner–phenotype associations in thoracic and head-and-neck NUT carcinoma

Management of toxicities from antibody – drug conjugates in breast cancer

Outcomes of critically ill pediatric patients after haploidentical stem cell transplantation